Can only be for the good to lift SBOTF out of the mire that is he OTC.Exposure to institutional investors with a product produced no where else should be a winner. Increasing use as a carrier in new drugs under FDA approval, expansion of production and increased revenues all looks good for future PPS jmo
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.